ksmaКубанский научный медицинский вестникKuban Scientific Medical Bulletin1608-62282541-9544Kuban State Medical University10.25207/1608-6228-2018-25-4-106-114ksma-1310Research ArticleОБЗОРЫREVIEWХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЕННОЙ ФРАКЦИЕЙ ВЫБРОСА: ЛЕЧЕНИЕ В УСЛОВИЯХ ОГРАНИЧЕННЫХ ДОКАЗАТЕЛЬСТВCHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCEКАНОРСКИЙС. Г.KANORSKIĬS. G.

ул. Седина, 4, Краснодар, Россия, 350063

тел.: 8(918) 355-82-81

Sedina str., 4, Krasnodar, Russia, 350063

tel.: 8(918) 355-82-81

kanorskysg@mail.ruБОРИСЕНКОЮ. В.BORISENKOJu. V.

ул. Седина, 4, Краснодар, Россия, 350063

Sedina str., 4, Krasnodar, Russia, 350063

СЕРЕДАА. Ф.SEREDAA. F.

ул. Седина, 4, Краснодар, Россия, 350063

Sedina str., 4, Krasnodar, Russia, 350063

Федеральное государственное бюджетное образовательное учреждение высшего образования «Кубанский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education Kuban State Medical University of the Ministry of Healthcare of the Russian FederationRussian Federation201803102018254106114Copyright © КАНОРСКИЙ С.Г., БОРИСЕНКО Ю.В., СЕРЕДА А.Ф., 20182018КАНОРСКИЙ С.Г., БОРИСЕНКО Ю.В., СЕРЕДА А.Ф.KANORSKIĬ S.G., BORISENKO J.V., SEREDA A.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ksma.elpub.ru/jour/article/view/1310

В статье обсуждаются современные представления о механизмах развития, результаты недавно завершенных и предпосылки новых исследований способов лечения хронической сердечной недостаточности с сохраненной фракцией выброса по данным литературы и собственных работ авторов.

The article discusses modern representation about the mechanisms of development, the results of recently completed and the background for  new studies of methods for treating chronic heart failure with preserved  ejection fraction according to the literature and authors' own works.

сердечная недостаточностьсохраненная фракция выбросалевый желудочекмеханизмылечениеheart failurepreserved ejection fractionleft ventriclemechanismstreatmentReferencesShah K.S., Xu H., Matsouaka R.A. et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017; 70(20): 2476-2486. DOI: 10.1016/j.jacc.2017.08.074.Shah K.S., Xu H., Matsouaka R.A. et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017; 70(20): 2476-2486. DOI: 10.1016/j.jacc.2017.08.074.Lam C.S.P., Gamble G.D., Ling L.H. et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018; 39(20): 1770-1780. DOI: 10.1093/eurheartj/ehy005.Lam C.S.P., Gamble G.D., Ling L.H. et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018; 39(20): 1770-1780. DOI: 10.1093/eurheartj/ehy005.Gladden J.D., Chaanine A.H., Redfield M.M. Heart Failure with Preserved Ejection Fraction. Annu Rev Med. 2018; 69: 65-79. DOI: 10.1146/annurev-med-041316-090654.Gladden J.D., Chaanine A.H., Redfield M.M. Heart Failure with Preserved Ejection Fraction. Annu Rev Med. 2018; 69: 65-79. DOI: 10.1146/annurev-med-041316-090654.Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129-2200. DOI: 10.1093/eurheartj/ehw128.Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129-2200. DOI: 10.1093/eurheartj/ehw128.Ezekowitz J.A., O'Meara E., McDonald M.A. et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017; 33(11): 1342-1433. DOI: 10.1016/j.cjca.2017.08.022.Ezekowitz J.A., O'Meara E., McDonald M.A. et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017; 33(11): 1342-1433. DOI: 10.1016/j.cjca.2017.08.022.Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136(6): e137-e161. DOI: 10.1161/CIR.0000000000000509.Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136(6): e137-e161. DOI: 10.1161/CIR.0000000000000509.Kotecha D., Lam C.S., Van Veldhuisen D.J. et al. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J Am Coll Cardiol. 2016; 68(20): 2217-2228. DOI: 10.1016/j.jacc.2016.08.048.Kotecha D., Lam C.S., Van Veldhuisen D.J. et al. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J Am Coll Cardiol. 2016; 68(20): 2217-2228. DOI: 10.1016/j.jacc.2016.08.048.Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887-98. DOI: 10.1056/NEJMoa0801369.Beckett N.S., Peters R., Fletcher A.E. et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887-98. DOI: 10.1056/NEJMoa0801369.Wright J.T. Jr., Williamson J.D., Whelton P.K. et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103-16. DOI: 10.1056/NEJMoa1511939.Wright J.T. Jr., Williamson J.D., Whelton P.K. et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103-16. DOI: 10.1056/NEJMoa1511939.Schwartzenberg S., Redfield M.M., From A.M. et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012; 59(5): 442-51. DOI: 10.1016/j.jacc.2011.09.062.Schwartzenberg S., Redfield M.M., From A.M. et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012; 59(5): 442-51. DOI: 10.1016/j.jacc.2011.09.062.Hwang S.J., Melenovsky V., Borlaug B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014; 63(25 Pt A): 2817-27. DOI: 10.1016/j.jacc.2014.03.034.Hwang S.J., Melenovsky V., Borlaug B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014; 63(25 Pt A): 2817-27. DOI: 10.1016/j.jacc.2014.03.034.Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386): 777-81.Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386): 777-81.Massie B.M., Carson P.E., McMurray J.J. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359(23): 2456-67. DOI: 10.1056/NEJMoa0805450.Massie B.M., Carson P.E., McMurray J.J. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359(23): 2456-67. DOI: 10.1056/NEJMoa0805450.Cleland J.G., Tendera M., Adamus J. et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27(19): 2338-45. DOI:10.1093/eurheartj/ehl250.Cleland J.G., Tendera M., Adamus J. et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27(19): 2338-45. DOI:10.1093/eurheartj/ehl250.Канорский С.Г., Трегубов В.Г., Покровский В.М. Преимущества терапии квинаприлом у пациентов с артериальной гипертензией и хронической сердечной недостаточностью I-II функционального класса и сохраненной фракцией выброса левого желудочка. Кардиология. 2012; 52(4): 31-37. [Kanorskiĭ S.G., Tregubov V.G., Pokrovskiĭ V.M. Preimushhestva terapii kvinaprilom u pacientov s arterial'noj gipertenziej i hronicheskoj serdechnoj nedostatochnost'ju I-II funkcional'nogo klassa i sohranennoj frakciej vybrosa levogo zheludochka. Kardiologija. 2012; 52(4): 31-37. (In Russ)].Канорский С.Г., Трегубов В.Г., Покровский В.М. Преимущества терапии квинаприлом у пациентов с артериальной гипертензией и хронической сердечной недостаточностью I-II функционального класса и сохраненной фракцией выброса левого желудочка. Кардиология. 2012; 52(4): 31-37. [Kanorskiĭ S.G., Tregubov V.G., Pokrovskiĭ V.M. Preimushhestva terapii kvinaprilom u pacientov s arterial'noj gipertenziej i hronicheskoj serdechnoj nedostatochnost'ju I-II funkcional'nogo klassa i sohranennoj frakciej vybrosa levogo zheludochka. Kardiologija. 2012; 52(4): 31-37. (In Russ)].Pitt B., Pfeffer M.A., Assmann S.F. et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15): 1383-92. DOI: 10.1056/NEJMoa1313731.Pitt B., Pfeffer M.A., Assmann S.F. et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15): 1383-92. DOI: 10.1056/NEJMoa1313731.Pfeffer M.A., Claggett B., Assmann S.F. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34-42. DOI: 10.1161/CIRCULATIONAHA.114. 013255.Pfeffer M.A., Claggett B., Assmann S.F. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1): 34-42. DOI: 10.1161/CIRCULATIONAHA.114. 013255.de Denus S., O'Meara E., Desai A.S. et al. Spironolactone Metabolites in TOPCAT – New Insights into Regional Variation. N Engl J Med. 2017; 376(17): 1690-1692. DOI: 10.1056/NEJMc1612601.de Denus S., O'Meara E., Desai A.S. et al. Spironolactone Metabolites in TOPCAT – New Insights into Regional Variation. N Engl J Med. 2017; 376(17): 1690-1692. DOI: 10.1056/NEJMc1612601.O'Neal W.T., Sandesara P.B., Samman-Tahhan A. et al. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2017; 24(11): 1212-1219. DOI: 10.1177/2047487317708676.O'Neal W.T., Sandesara P.B., Samman-Tahhan A. et al. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2017; 24(11): 1212-1219. DOI: 10.1177/2047487317708676.Bavishi C., Chatterjee S., Ather S. et al. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015; 20(2): 193-201. DOI: 10.1007/s10741-014-9453-8.Bavishi C., Chatterjee S., Ather S. et al. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015; 20(2): 193-201. DOI: 10.1007/s10741-014-9453-8.Gloekler S., Traupe T., Stoller M. et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. et al. Heart. 2014; 100(2): 160-6. DOI: 10.1136/heartjnl-2013-304880.Gloekler S., Traupe T., Stoller M. et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. et al. Heart. 2014; 100(2): 160-6. DOI: 10.1136/heartjnl-2013-304880.Reil J.C., Hohl M., Reil G.H. et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2013; 34(36): 2839-49. DOI: 10.1093/eurheartj/ ehs218.Reil J.C., Hohl M., Reil G.H. et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2013; 34(36): 2839-49. DOI: 10.1093/eurheartj/ ehs218.Канорский С.Г., Борисенко Ю.В. Сравнительная оценка β-адреноблокатора и ингибитора if-каналов у больных с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка. Кардиология. 2016; 56(2): 24-29. [Kanorskiĭ S.G., Borisenko Ju.V. Sravnitel'naja ocenka β-adrenoblokatora i ingibitora if- kanalov u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju i sohranennoj frakciej vybrosa levogo zheludochka. Kardiologija. 2016; 56(2): 24-29. (In Russ)].Канорский С.Г., Борисенко Ю.В. Сравнительная оценка β-адреноблокатора и ингибитора if-каналов у больных с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка. Кардиология. 2016; 56(2): 24-29. [Kanorskiĭ S.G., Borisenko Ju.V. Sravnitel'naja ocenka β-adrenoblokatora i ingibitora if- kanalov u bol'nyh s hronicheskoj serdechnoj nedostatochnost'ju i sohranennoj frakciej vybrosa levogo zheludochka. Kardiologija. 2016; 56(2): 24-29. (In Russ)].Redfield M.M., Anstrom K.J., Levine J.A. et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015; 373(24): 2314-24. DOI: 10.1056/NEJMoa1510774.Redfield M.M., Anstrom K.J., Levine J.A. et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015; 373(24): 2314-24. DOI: 10.1056/NEJMoa1510774.Davis B.R., Kostis J.B., Simpson L.M. et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008; 118(22): 2259-67. DOI: 10.1161/CIRCULATIONAHA.107.762229.Davis B.R., Kostis J.B., Simpson L.M. et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008; 118(22): 2259-67. DOI: 10.1161/CIRCULATIONAHA.107.762229.Канорский С.Г., Середа А.Ф. Сравнение верапамила и амлодипина при лечении хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка у пациентов гипертонической болезнью. Кардиология. 2016; 56(12): 27-32. [Kanorskiĭ S.G., Sereda A.F. Sravnenie verapamila i amlodipina pri lechenii hronicheskoj serdechnoj nedostatochnosti s sohranennoj frakciej vybrosa levogo zheludochka u pacientov gipertonicheskoj bolezn'ju. Kardiologija. 2016; 56(12): 27-32. (In Russ)].Канорский С.Г., Середа А.Ф. Сравнение верапамила и амлодипина при лечении хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка у пациентов гипертонической болезнью. Кардиология. 2016; 56(12): 27-32. [Kanorskiĭ S.G., Sereda A.F. Sravnenie verapamila i amlodipina pri lechenii hronicheskoj serdechnoj nedostatochnosti s sohranennoj frakciej vybrosa levogo zheludochka u pacientov gipertonicheskoj bolezn'ju. Kardiologija. 2016; 56(12): 27-32. (In Russ)].Fukuta H., Goto T., Wakami K. et al. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta- analysis of propensity score analyses. Int J Cardiol. 2016; 214: 301-6. DOI: 10.1016/j.ijcard.2016.03.186.Fukuta H., Goto T., Wakami K. et al. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta- analysis of propensity score analyses. Int J Cardiol. 2016; 214: 301-6. DOI: 10.1016/j.ijcard.2016.03.186.Канорский С.Г., Середа А.Ф. Применение статинов у пациентов с гипертонической болезнью и хронической сердечной недостаточностью с сохраненной фракцией выброса левого желудочка. Фарматека. 2017; 15(348): 37-42. [Kanorskiĭ S.G., Sereda A.F. Primenenie statinov u pacientov s gipertonicheskoj bolezn'ju i hronicheskoj serdechnoj nedostatochnost'ju s sohranennoj frakciej vybrosa levogo zheludochka. Farmateka. 2017; 15(348): 37-42].Канорский С.Г., Середа А.Ф. Применение статинов у пациентов с гипертонической болезнью и хронической сердечной недостаточностью с сохраненной фракцией выброса левого желудочка. Фарматека. 2017; 15(348): 37-42. [Kanorskiĭ S.G., Sereda A.F. Primenenie statinov u pacientov s gipertonicheskoj bolezn'ju i hronicheskoj serdechnoj nedostatochnost'ju s sohranennoj frakciej vybrosa levogo zheludochka. Farmateka. 2017; 15(348): 37-42].Zakeri R., Cowie M.R. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart. 2018; 104(5): 377-384. DOI: 10.1136/heartjnl-2016-310790.Zakeri R., Cowie M.R. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart. 2018; 104(5): 377-384. DOI: 10.1136/heartjnl-2016-310790.Lam C.S.P., Voors A.A., de Boer R.A. et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018 Jun 13. DOI: 10.1093/eurheartj/ehy301. [Epub ahead of print].Lam C.S.P., Voors A.A., de Boer R.A. et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018 Jun 13. DOI: 10.1093/eurheartj/ehy301. [Epub ahead of print].Shah A.M., Claggett B., Loehr L.R. et al. Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. 2017; 135(3): 224- 240. DOI: 10.1161/CIRCULATIONAHA.116.023361.Shah A.M., Claggett B., Loehr L.R. et al. Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation. 2017; 135(3): 224- 240. DOI: 10.1161/CIRCULATIONAHA.116.023361.Reddy Y.N.V., Andersen M.J., Obokata M. et al. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 70(2): 136-148. DOI: 10.1016/j.jacc.2017.05.029.Reddy Y.N.V., Andersen M.J., Obokata M. et al. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 70(2): 136-148. DOI: 10.1016/j.jacc.2017.05.029.Freed B.H., Daruwalla V., Cheng J.Y. et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging. 2016; 9(3): e003754. DOI: 10.1161/CIRCIMAGING.115.003754.Freed B.H., Daruwalla V., Cheng J.Y. et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging. 2016; 9(3): e003754. DOI: 10.1161/CIRCIMAGING.115.003754.Feldman T., Mauri L., Kahwash R. et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham- Controlled Trial. Circulation. 2018; 137(4): 364-375. DOI: 10.1161/CIRCULATIONAHA.117.032094.Feldman T., Mauri L., Kahwash R. et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham- Controlled Trial. Circulation. 2018; 137(4): 364-375. DOI: 10.1161/CIRCULATIONAHA.117.032094.Adamson P.B., Abraham W.T., Bourge R.C. et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014; 7(6): 935-44. DOI: 10.1161/CIRCHEARTFAILURE.113.001229.Adamson P.B., Abraham W.T., Bourge R.C. et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014; 7(6): 935-44. DOI: 10.1161/CIRCHEARTFAILURE.113.001229.Heywood J.T., Jermyn R., Shavelle D. et al. Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. Circulation. 2017; 135(16): 1509-1517. DOI: 10.1161/CIRCULATIONAHA.116.026184.Heywood J.T., Jermyn R., Shavelle D. et al. Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. Circulation. 2017; 135(16): 1509-1517. DOI: 10.1161/CIRCULATIONAHA.116.026184.Gorter T.M., Hoendermis E.S., van Veldhuisen D.J. et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2016; 18(12): 1472-1487. DOI: 10.1002/ejhf.630.Gorter T.M., Hoendermis E.S., van Veldhuisen D.J. et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2016; 18(12): 1472-1487. DOI: 10.1002/ejhf.630.Gorter T.M., van Veldhuisen D.J., Voors A.A. et al. Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2018; 19(4): 425-432. DOI: 10.1093/ehjci/jex133.Gorter T.M., van Veldhuisen D.J., Voors A.A. et al. Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2018; 19(4): 425-432. DOI: 10.1093/ehjci/jex133.Gorter T.M., van Veldhuisen D.J., Bauersachs J. et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(1): 16-37. DOI: 10.1002/ejhf.1029.Gorter T.M., van Veldhuisen D.J., Bauersachs J. et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(1): 16-37. DOI: 10.1002/ejhf.1029.Fayyaz A.U., Edwards W.D., Maleszewski J.J. et al. Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation. 2018; 137(17): 1796-1810. DOI: 10.1161/CIRCULATIONAHA.117.031608.Fayyaz A.U., Edwards W.D., Maleszewski J.J. et al. Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation. 2018; 137(17): 1796-1810. DOI: 10.1161/CIRCULATIONAHA.117.031608.Gorter T.M., van Veldhuisen D.J., Bauersachs J. et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(1): 16-37. DOI: 10.1002/ejhf.1029.Gorter T.M., van Veldhuisen D.J., Bauersachs J. et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(1): 16-37. DOI: 10.1002/ejhf.1029.Obokata M., Reddy Y.N.V., Pislaru S.V. et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017; 136(1): 6-19. DOI: 10.1161/CIRCULATIONAHA.116.026807.Obokata M., Reddy Y.N.V., Pislaru S.V. et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017; 136(1): 6-19. DOI: 10.1161/CIRCULATIONAHA.116.026807.Hallow K.M., Helmlinger G., Greasley P.J. et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018; 20(3): 479-487. DOI: 10.1111/dom.13126.Hallow K.M., Helmlinger G., Greasley P.J. et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018; 20(3): 479-487. DOI: 10.1111/dom.13126.Hallow K.M., Greasley P.J., Helmlinger G. et al. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol. 2018 Jul 18. DOI: 10.1152/ajprenal.00202.2018. [Epub ahead of print]Hallow K.M., Greasley P.J., Helmlinger G. et al. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol. 2018 Jul 18. DOI: 10.1152/ajprenal.00202.2018. [Epub ahead of print]Van Tassell B.W., Canada J.M., Buckley L.F. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: the Diastolic Heart Failure Anakinra Response Trial 2 (DHART2). Circulation. 2017; 136: A17709.Van Tassell B.W., Canada J.M., Buckley L.F. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: the Diastolic Heart Failure Anakinra Response Trial 2 (DHART2). Circulation. 2017; 136: A17709.Pieske B., Maggioni A.P., Lam C.S.P. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATESPRESERVED) study. Eur Heart J. 2017; 38(15): 1119-1127. DOI: 10.1093/eurheartj/ehw593.Pieske B., Maggioni A.P., Lam C.S.P. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATESPRESERVED) study. Eur Heart J. 2017; 38(15): 1119-1127. DOI: 10.1093/eurheartj/ehw593.Filippatos G., Maggioni A.P., Lam C.S.P. et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES- PRESERVED) study. Eur J Heart Fail. 2017; 19(6): 782-791. DOI: 10.1002/ejhf.800.Filippatos G., Maggioni A.P., Lam C.S.P. et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES- PRESERVED) study. Eur J Heart Fail. 2017; 19(6): 782-791. DOI: 10.1002/ejhf.800.Solomon S.D., Zile M., Pieske B. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380(9851): 1387-95. DOI: 10.1016/S0140-6736(12)61227-6.Solomon S.D., Zile M., Pieske B. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380(9851): 1387-95. DOI: 10.1016/S0140-6736(12)61227-6.Solomon S.D., Rizkala A.R., Lefkowitz M.P. et al. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018; 11(7): e004962. DOI: 10.1161/CIRCHEARTFAILURE.118.004962.Solomon S.D., Rizkala A.R., Lefkowitz M.P. et al. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018; 11(7): e004962. DOI: 10.1161/CIRCHEARTFAILURE.118.004962.Noordali H., Loudon B.L., Frenneaux M.P. et al. Cardiac metabolism – A promising therapeutic target for heart failure. Pharmacol Ther. 2018; 182: 95-114. DOI: 10.1016/ j.pharmthera.2017.08.001.Noordali H., Loudon B.L., Frenneaux M.P. et al. Cardiac metabolism – A promising therapeutic target for heart failure. Pharmacol Ther. 2018; 182: 95-114. DOI: 10.1016/ j.pharmthera.2017.08.001.Lopaschuk G.D. Metabolic Modulators in Heart Disease: Past, Present, and Future. Can J Cardiol. 2017; 33(7): 838-849. DOI: 10.1016/j.cjca.2016.12.013.Lopaschuk G.D. Metabolic Modulators in Heart Disease: Past, Present, and Future. Can J Cardiol. 2017; 33(7): 838-849. DOI: 10.1016/j.cjca.2016.12.013.Steggall A., Mordi I.R., Lang C.C. Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. Diseases. 2017; 5(2): E14. DOI: 10.3390/diseases5020014.Steggall A., Mordi I.R., Lang C.C. Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. Diseases. 2017; 5(2): E14. DOI: 10.3390/diseases5020014.Zile M.R., Baicu C.F., Ikonomidis J.S. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015; 131(14): 1247- 59. DOI: 10.1161/CIRCULATIONAHA.114.013215.Zile M.R., Baicu C.F., Ikonomidis J.S. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015; 131(14): 1247- 59. DOI: 10.1161/CIRCULATIONAHA.114.013215.Suthahar N., Meijers W.C., Silljé H.H.W. et al. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018; 8(3): 593-609. DOI: 10.7150/thno.22196.Suthahar N., Meijers W.C., Silljé H.H.W. et al. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018; 8(3): 593-609. DOI: 10.7150/thno.22196.

The authors declare that there are no conflicts of interest present.